Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 2011. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary shares by nine individuals on December 9, 2011, at a price of 1,426.75 pence per share through the Company's Share Reward Plan. The transactions involved both personal contributions and company matching contributions:
- Mr A P Witty: Acquired 9 shares (personal) and 9 shares (company match).
- Mr S Dingemans: Acquired 9 shares (personal) and 9 shares (company match).
- Mr S M Bicknell: Acquired 9 shares (personal) and 9 shares (company match).
- Mr E J Gray: Acquired 9 shares (personal) and 9 shares (company match).
- Mr D S Redfern: Acquired 9 shares (personal) and 9 shares (company match).
- Ms C Thomas: Acquired 9 shares (personal) and 9 shares (company match).
- Mr P C Thomson: Acquired 6 shares (personal) and 6 shares (company match).
- Dr P J T Vallance: Acquired 8 shares (personal) and 8 shares (company match).
- Mrs V A Whyte: Acquired 9 shares (personal) and 9 shares (company match).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of share ownership changes in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of 1,426.75 pence per Ordinary share on December 9, 2011.
- Confirm the total number of shares acquired by each listed director under the Share Reward Plan.
- Review the company's annual report (Form 20-F) for comprehensive financial performance data, as this filing contains none.